Mostrar el registro sencillo del ítem

dc.contributor.authorDíaz Prado, Silvia María
dc.contributor.authorMuiños López, Emma
dc.contributor.authorHermida Gómez, Tamara 
dc.contributor.authorCicione, Claudia
dc.contributor.authorRendal Vázquez, Esther 
dc.contributor.authorFuentes Boquete, Isaac
dc.contributor.authorDe Toro Santos, Francisco Javier 
dc.contributor.authorBLANCO GARCIA, FRANCISCO JAVIER 
dc.date.accessioned2017-06-07T07:07:09Z
dc.date.available2017-06-07T07:07:09Z
dc.date.issued2011
dc.identifier.issn0301-4681
dc.identifier.urihttp://hdl.handle.net/20.500.11940/2812
dc.description.abstractThe human amniotic membrane (HAM) is a highly abundant and readily available tissue. This amniotic tissue has considerable advantageous characteristics to be considered as an attractive material in the field of regenerative medicine. It has low immunogenicity, anti-inflammatory properties and their cells can be isolated without the sacrifice of human embryos. Since it is discarded post-partum it may be useful for regenerative medicine and cell therapy. Amniotic membranes have already been used extensively as biologic dressings in ophthalmic, abdominal and plastic surgery. HAM contains two cell types, from different embryological origins, which display some characteristic properties of stem cells. Human amnion epithelial cells (hAECs) are derived from the embryonic ectoderm, while human amnion mesenchymal stromal cells (hAMSCs) are derived from the embryonic mesoderm. Both populations have similar immunophenotype and multipotential for in vitro differentiation into the major mesodermal lineages, however they differ in cell yield. Therefore, HAM has been proposed as a good candidate to be used in cell therapy or regenerative medicine to treat damaged or diseased tissues.
dc.language.isoeng
dc.rightsAtribución-Non comercial-Non derivadas 4.0 Internacional
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.gl
dc.titleHuman amniotic membrane as an alternative source of stem cells for regenerative medicine
dc.typeArtigoes
dc.authorsophosDiaz-Prado, S.
dc.authorsophosMuinos-Lopez, E.
dc.authorsophosHermida-Gomez, T.
dc.authorsophosCicione, C.
dc.authorsophosRendal-Vazquez, M. E.
dc.authorsophosFuentes-Boquete, I.
dc.authorsophosde Toro, F. J.
dc.authorsophosBlanco, F. J.
dc.identifier.doi10.1016/j.diff.2011.01.005
dc.identifier.isi288431000004
dc.identifier.pmid21339039
dc.identifier.sophos9083
dc.issue.number3
dc.journal.titleDIFFERENTIATION
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña::INIBIC.- Instituto de Investigación Biomédica
dc.page.initial162
dc.page.final71
dc.rights.accessRightsopenAccess
dc.typesophosArtículo Original
dc.volume.number81


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-Non comercial-Non derivadas 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-Non comercial-Non derivadas 4.0 Internacional